Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Astellas Pharma US, Inc
Femme et Homme Max 99 ans
Astellas Pharma US, Inc
MAJ Il y a 4 ans
A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Escalation Study to Assess the Safety and Effects of Intravenous Conivaptan on the Hepatic Hemodynamic Response in Stable Euvolemic or Hypervolemic Cirrhotic Patients Estudio fase II, randomizado, doble ciego, controlado con placebo, de escalonamiento de dosis para evaluar la seguridad y los efectos de Conivaptan intravenoso sobre la respuesta hemodinámica hepática en pacientes cirróticos euvolémicos o hipervolémicos estables
The objectives of this study are to evaluate the safety of two different doses of IV conivaptan (YM087 or Vaprisol®) in stable euvolemic or hypervolemic cirrhotic patients with serum sodium 115 – 140 ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Astellas Pharma US, Inc
MAJ Il y a 4 ans
A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multi-Center Study to Evaluate the Safety of the Co-administration of Solifenacin Succinate with 0.4 mg Tamsulosin Hydrochloride OCAS (TOCAS) Using Urodynamics in Male Subjects with Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)
The primary objective of this study is to evaluate the urodynamic variables of male subjects with LUTS and BOO treated with the co-administration of 6 mg solifenacin succinate and TOCAS, and 9 mg soli...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma US, Inc
MAJ Il y a 4 ans
A Phase 3, Multi-Center, Open Label Safety Study of RSD1235 in Subjects with Atrial Fibrillation
To evaluate the safety of RSD1235 in subjects with atrial fibrillation (AF).
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma US, Inc
MAJ Il y a 4 ans
A PHASE III PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, TOLERANCE AND EFFICACY STUDY OF RSD1235 IN SUBJECTS WITH ATRIAL FIBRILLATION OR ATRIAL FLUTTER
To demonstrate the efficacy of RSD1235 compared with placebo, in the conversion of AF or AFL to SR. Treatment will be considered successful if there is a treatment-induced conversion of atrial arrhyt...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Astellas Pharma US, Inc
MAJ Il y a 4 ans
A Phase II Multicenter, Open-Label Study of YM155 in Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subjects
To evaluate the overall response rate (Complete Remission + Partial Remission) of YM155 per the International Working Group Criteria (IWG, 2007) during 15 cycles of treatment.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations